Last reviewed · How we verify

DTacP-IPV combined vaccine (TETRAXIM™)

Sanofi · FDA-approved active Biologic Quality 22/100

DTacP-IPV combined vaccine (TETRAXIM™) is a Combination inactivated vaccine Biologic drug developed by Sanofi. It is currently FDA-approved for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in children 6 weeks through 6 years of age. Also known as: TETRAXIM™.

TETRAXIM™ is a combination vaccine manufactured by Sanofi that provides immunization against four major childhood infectious diseases: diphtheria, tetanus, pertussis, and poliomyelitis. Indicated for children aged 6 weeks through 6 years, this marketed product represents a well-established standard of care in pediatric immunization programs globally. The vaccine combines inactivated poliovirus vaccine (IPV) with diphtheria, tetanus, and acellular pertussis (DTacP) components in a single injection, reducing the number of shots required during childhood vaccination schedules. With 2 clinical trials supporting its safety and efficacy profile, TETRAXIM™ has become a cornerstone product in Sanofi's vaccine portfolio. The combination formulation offers significant commercial value through improved compliance and convenience for healthcare providers and parents, though specific revenue figures are not disclosed.

At a glance

Generic nameDTacP-IPV combined vaccine (TETRAXIM™)
Also known asTETRAXIM™
SponsorSanofi
Drug classCombination inactivated vaccine
TargetDiphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTacP-IPV combined vaccine (TETRAXIM™)

What is DTacP-IPV combined vaccine (TETRAXIM™)?

DTacP-IPV combined vaccine (TETRAXIM™) is a Combination inactivated vaccine drug developed by Sanofi, indicated for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in children 6 weeks through 6 years of age.

What is DTacP-IPV combined vaccine (TETRAXIM™) used for?

DTacP-IPV combined vaccine (TETRAXIM™) is indicated for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in children 6 weeks through 6 years of age.

Who makes DTacP-IPV combined vaccine (TETRAXIM™)?

DTacP-IPV combined vaccine (TETRAXIM™) is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is DTacP-IPV combined vaccine (TETRAXIM™) also known as anything else?

DTacP-IPV combined vaccine (TETRAXIM™) is also known as TETRAXIM™.

What drug class is DTacP-IPV combined vaccine (TETRAXIM™) in?

DTacP-IPV combined vaccine (TETRAXIM™) belongs to the Combination inactivated vaccine class. See all Combination inactivated vaccine drugs at /class/combination-inactivated-vaccine.

What development phase is DTacP-IPV combined vaccine (TETRAXIM™) in?

DTacP-IPV combined vaccine (TETRAXIM™) is FDA-approved (marketed).

What does DTacP-IPV combined vaccine (TETRAXIM™) target?

DTacP-IPV combined vaccine (TETRAXIM™) targets Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3 and is a Combination inactivated vaccine.

Related